MTOR and nasopharyngeal carcinoma: To further determine whether activation of the PTEN/AKT/mTOR signalling pathway is important for the oncogenic activity of EpCAM in NPC cells, EpCAM-expressing S-18 and 6–10B cells were treated with the pharmacological AKT inhibitor MK2206 or the mTOR inhibitor rapamycin.